Newsroom

LONDON--(BUSINESS WIRE)--  Re: ERM FUNDING PLC. GBP 100.00 MATURING: 31-Dec-2099 ISIN: XS2351471060 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 15-Oct-2025 TO 15-Jan-2026 HAS BEEN FIXED AT .00 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 15-Jan-2026 WILL AMOUNT TO: GBP .00 PER GBP 100.00 DENOMINATION  ...

LONDON--(BUSINESS WIRE)--  Re: Atlas Funding 2024-1 PLC GBP 1,995,000.00 MATURING: 20-Sep-2061 ISIN: XS2819820361 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 22-Dec-2025 TO 20-Jan-2026 HAS BEEN FIXED AT 8.01 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 20-Jan-2026 WILL AMOUNT TO: GBP 13,351.96 PER GBP 2,097,878.83 DENOMINATION  ...

LONDON--(BUSINESS WIRE)--  As Agent Bank, please be advised of the following rate determined on: 1/12/2026 Issue ¦ Westpac Banking Corporation Series No 1538 USD 15,000,000 FRN Due in Jan 2034     ISIN Number ¦ XS2751583050 ISIN Reference ¦ 275158305 Issue Nomin USD ¦ 15000000 Period ¦ 10/20/2025 to 1/20/2026   Payment Date 1/20/2026 Number of Days ¦ 92 Rate ¦ 5.01118   Denomination USD ¦ 200000   ¦ 15000000   ¦       Amount Payable per Denomination ¦ 2561.27   ¦ 192095.25   ¦       Bank of New...

LONDON--(BUSINESS WIRE)--  Re: ATLAS FUNDING 2023 -1 PLC GBP 5,790,000.00 MATURING: 20-Jan-2061 ISIN: XS2601581981 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 22-Dec-2025 TO 20-Jan-2026 HAS BEEN FIXED AT 7.59 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 20-Jan-2026 WILL AMOUNT TO: GBP 36,757.77 PER GBP 6,095,000.00 DENOMINATION  ...

SAN FRANCISCO--(BUSINESS WIRE)--Bunkerhill Health today announced the system-wide deployment of its Carebricks platform at the University of Texas Medical Branch, enabling clinician-led, agentic AI workflows that support care delivery across a health system serving over one million patient visits annually. Over the past year, UTMB Health has moved beyond isolated AI initiatives by deploying Bunkerhill’s Carebricks platform to translate clinician- and operator-led ideas into system-wide action....

LONDON--(BUSINESS WIRE)--  Re: FOSSE MASTER ISSUER PLC GBP 500,000,000.00 MATURING: 18-Oct-2072 ISIN: XS2065729654 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 20-Oct-2025 TO 20-Jan-2026 HAS BEEN FIXED AT 4.81 PCT DAY BASIS: ACTUAL/365(PROP) INTEREST PAYABLE VALUE 20-Jan-2026 WILL AMOUNT TO: GBP 6,062,774.79 PER GBP 500,000,000.00 DENOMINATION  ...

LONDON--(BUSINESS WIRE)--  Re: ATLAS FUNDING 2023 -1 PLC GBP 18,818,000.00 MATURING: 20-Jan-2061 ISIN: XS2601487023 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 22-Dec-2025 TO 20-Jan-2026 HAS BEEN FIXED AT 5.69 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 20-Jan-2026 WILL AMOUNT TO: GBP 89,560.83 PER GBP 19,809,000.00 DENOMINATION  ...

LONDON--(BUSINESS WIRE)--  As Agent Bank, please be advised of the following rate determined on: 1/13/2026 Issue ¦ Delamare Cards MTN Issuer plc Series 2023 - 2 Class - A2 GBP 200,000,000 FRN Due in Oct 2028     ISIN Number ¦ XS2697482656 ISIN Reference ¦ 269748265 Issue Nomin GBP ¦ 200000000 Period ¦ 12/19/2025 to 1/20/2026   Payment Date 1/20/2026 Number of Days ¦ 32 Rate ¦ 4.85883   Denomination GBP ¦ 1000   ¦ 200000000   ¦       Amount Payable per Denomination ¦ 4.26   ¦ 851959.23   ¦      ...

SAN CARLOS, Califórnia--(BUSINESS WIRE)--A BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), empresa global de oncologia, apresentará hoje os pilares de sua crescente liderança global em oncologia durante sua apresentação na 44ª Conferência Anual de Saúde do J.P. Morgan, em San Francisco. John V. Oyler, cofundador, presidente do conselho e CEO da BeOne, destacará a liderança transformadora da empresa no tratamento das malignidades de células B. A apresentação trará o BRUKINSA®, líde...

SAN CARLOS, California--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), una empresa global de oncología, presentará hoy los ejes de su creciente posicionamiento internacional durante su participación en la 44.a Conferencia Anual de Salud de J.P. Morgan, que se celebra en San Francisco. John V. Oyler, cofundador, presidente y director ejecutivo de BeOne, destacará el impacto transformador de la empresa en el tratamiento de malignidades de células B. La presentación...